Logo
x

Search category

Subscribe Now

Noven

Insights+: The US FDA New Drug Approvals in March 2022

Insights+: The US FDA New Drug Approvals in March 2022

  • April 21, 2022
Noven’s Xelstrym (dextroamphetamine) Transdermal System Receives the US FDA’s Approval for the Treatment of ADHD

Noven’s Xelstrym (dextroamphetamine) Transdermal System Receives the US FDA’s Approval for the Treatment of ADHD

  • March 23, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.